Thank You for Over 40 Years of Trust

Since 1984, ELISA/ACT Biotechnologies (EAB), home of the LRA by ELISA/ACT testing, has been a pioneering force in personalized immunology, offering the most comprehensive and clinically insightful ex‑vivo testing for delayed hypersensitivities.

Developed by Russell M. Jaffe, MD, PhD, CCN, NACB, the patented Lymphocyte Response Assay (LRA) by ELISA/ACT directly assesses lymphocyte responses to detect all three types of delayed hypersensitivity reactions to foods and environmental chemicals—providing unparalleled insight into immune tolerance and overload.

These tests have empowered thousands of clinicians to uncover hidden immune triggers at the root of chronic conditions and to help their patients find lasting relief and improved quality of life. We remain deeply grateful for the trust and collaboration from our practitioner community and those they serve.

Looking Ahead

After thoughtful reflection, we have made the decision to discontinue ELISA/ACT Biotechnologies operations. The LRA by ELISA/ACT tests that defined our legacy will not return. However, our commitment to root‑cause, integrative health remains strong.

We are now fully focused on the growth and expansion of our sister company, PERQUE Integrative Health, which carries Dr. Jaffe's science‑based legacy through innovative nutritional solutions and clinical protocols.

Explore PERQUE Integrative Health

Continued Support

As part of our ongoing support to the community, we are excited to share our comprehensive Microbiome Support Protocol—a combination of well‑studied, readily available Dr. Jaffe‑recommended tests and targeted PERQUE nutraceuticals, designed to assess inflammation, repair deficit, gut restoration, and immune balance.

Access the Microbiome Support Protocol

Thank you for being a part of the LRA by ELISA/ACT journey. Your support over the years has been invaluable, and we look forward to continuing to support your health goals through PERQUE.

With sincere appreciation,
The EAB Team